Differentiating Ischemic Hepatitis from Acetaminophen Overdose in Acute Liver Failure: Role of Acetaminophen Adducts-Ischemic Hepatitis vs Acetaminophen Overdose.
Acetaminophen overdose
Cardiac dysfunction
Hepatic necrosis
Hypoxia
Shock liver
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
received:
15
05
2024
accepted:
18
08
2024
medline:
2
9
2024
pubmed:
2
9
2024
entrez:
2
9
2024
Statut:
aheadofprint
Résumé
Acetaminophen (APAP) hepatotoxicity and ischemic hepatic injury (IH) demonstrate remarkably similar biochemical patterns. Deciding between these two etiologies in the setting of acute liver failure (ALF) can be challenging. We reviewed all cases in the Acute Liver Failure Study Group (ALFSG) registry where these diagnoses were considered, to determine reasons for, and frequency of, difficulties making these diagnoses. We hypothesized that the newly developed APAP-CYS adduct assay could help in discerning the correct diagnosis. Among 3364 patients with ALF or acute liver injury (ALI: INR ≥ 2.0 but without encephalopathy) between 1998 and 2019, 1952 (58%) received a final diagnosis of either APAP (1681) or IH (271). We utilized a review committee of senior hepatologists as well as the APAP-CYS assay (where sera were available), measuring the presence of toxic by-products of APAP injury to optimize adjudication. With these methods, a total of 575 adduct positive APAP cases included 488 recognized APAP, as well as an additional 87 patients previously diagnosed as other etiologies. Nine cases initially attributed to IH were deemed combination APAP-IH injuries. Conversely, 215 of the 280 IH subjects tested for adducts disclosed 173 confirmed as IH with adduct testing below the toxicity threshold, while 9 cases were revised from APAP to the IH-APAP combination phenotype, where both hypotension and APAP likely played a role. Discerning APAP from IH can be difficult-in rare cases, combined injury is observed (18/1952). APAP-CYS testing resulted in revising the diagnosis in 14.6% of cases.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Acetaminophen (APAP) hepatotoxicity and ischemic hepatic injury (IH) demonstrate remarkably similar biochemical patterns. Deciding between these two etiologies in the setting of acute liver failure (ALF) can be challenging. We reviewed all cases in the Acute Liver Failure Study Group (ALFSG) registry where these diagnoses were considered, to determine reasons for, and frequency of, difficulties making these diagnoses. We hypothesized that the newly developed APAP-CYS adduct assay could help in discerning the correct diagnosis.
METHODS
METHODS
Among 3364 patients with ALF or acute liver injury (ALI: INR ≥ 2.0 but without encephalopathy) between 1998 and 2019, 1952 (58%) received a final diagnosis of either APAP (1681) or IH (271). We utilized a review committee of senior hepatologists as well as the APAP-CYS assay (where sera were available), measuring the presence of toxic by-products of APAP injury to optimize adjudication.
RESULTS
RESULTS
With these methods, a total of 575 adduct positive APAP cases included 488 recognized APAP, as well as an additional 87 patients previously diagnosed as other etiologies. Nine cases initially attributed to IH were deemed combination APAP-IH injuries. Conversely, 215 of the 280 IH subjects tested for adducts disclosed 173 confirmed as IH with adduct testing below the toxicity threshold, while 9 cases were revised from APAP to the IH-APAP combination phenotype, where both hypotension and APAP likely played a role.
CONCLUSIONS
CONCLUSIONS
Discerning APAP from IH can be difficult-in rare cases, combined injury is observed (18/1952). APAP-CYS testing resulted in revising the diagnosis in 14.6% of cases.
Identifiants
pubmed: 39222204
doi: 10.1007/s10620-024-08602-7
pii: 10.1007/s10620-024-08602-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Yoon E, Babar A, Choudhary M et al. Acetaminophen-induced hepatotoxicity: A comprehensive update. J Clin Transl Hepatol 2016;4:131–142.
pubmed: 27350943
pmcid: 4913076
Larson AM, Polson J, Fontana RJ et al. Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. Hepatology 2005;42:1364–1372.
doi: 10.1002/hep.20948
pubmed: 16317692
Jaeschke H. Acetaminophen: Dose-dependent drug hepatotoxicity and acute liver failure in patients. Dig Dis 2015;33:464–471.
doi: 10.1159/000374090
pubmed: 26159260
Taylor RM, Tujios S, Jinjuvadia K et al. Short and long-term outcomes in patients with acute liver failure due to ischemic hepatitis. Dig Dis Sci 2012;57:777–785. https://doi.org/10.1007/s10620-011-1918-1 .
doi: 10.1007/s10620-011-1918-1
pubmed: 21948394
Lightsey J, Rockey D. Current concepts in ischemic hepatitis. Curr Opin Gastroenterol 2017;33:158–163.
doi: 10.1097/MOG.0000000000000355
pubmed: 28346236
Gibson P, Colman J, Wood L et al. Serum enzyme pattern in acute liver disease: Relation to type of cell death. J Gastroenterol Hepatol 1987;2:419–422.
doi: 10.1111/j.1440-1746.1987.tb00185.x
Gulliver J, Dalton H, Aithal G et al. Temporal change and phenotypic pattern of liver function tests can distinguish ischaemic hepatitis from drug induced liver injury—a large 6-year retrospective cohort analysis. Gut 2017;66:A170–A171.
Weemhoff J, Woolbright B, Jenkins R et al. Plasma biomarkers to study mechanisms of liver injury in patients with hypoxic hepatitis. Liver Internat 2016;37:377–384.
doi: 10.1111/liv.13202
McGill MR, Staggs VS, Sharpe MR et al. Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome. Hepatology 2014;60:1336–1345.
doi: 10.1002/hep.27265
pubmed: 24923598
Tapper E, Sengupta N, Bonder A. The Incidence and outcomes of ischemic hepatitis: A systematic review with meta-analysis. Am J Med 2015;128:1314–1321.
doi: 10.1016/j.amjmed.2015.07.033
pubmed: 26299319
Davern TJ II, James LP, Hinson JA et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006;130:687–694.
doi: 10.1053/j.gastro.2006.01.033
pubmed: 16530510
Leventhal TM, Gottfried M, Olson JC et al. Acetaminophen is undetectable in plasma form more than half of patients believed to have acute liver failure due to overdose. Clin Gastro Hepatol 2019;17:2110–2116.
doi: 10.1016/j.cgh.2019.01.040
James LP, Letzig LG, Simpson PM, Capparelli E, Roberts DW, Hinson JA. Pharmacokinetics of acetaminophen protein adducts in adults with acetaminophen overdose and acute liver failure. Drug Metab Dispos 2009;37:1779–1784.
doi: 10.1124/dmd.108.026195
pubmed: 19439490
pmcid: 2712440
Koch DG, Speiser JL, Durkalski V et al. The natural history of severe acute liver injury. Am J Gastroenterol 2017;112:1389–1396.
doi: 10.1038/ajg.2017.98
pubmed: 28440304
pmcid: 5587371
Fontana RJ, Ellerbe C, Durkalski VE et al. Two-year outcomes in Initial survivors with acute liver failure: results from a prospective, multicenter study. Liver Int 2015;35:370–380.
doi: 10.1111/liv.12632
pubmed: 25039930
Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947–954.
doi: 10.7326/0003-4819-137-12-200212170-00007
pubmed: 12484709
Khandelwal N, James LP, Sanders C et al. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology 2011;53:567–576.
doi: 10.1002/hep.24060
pubmed: 21274877
Fontana RJ, Engle RE, Scaglione S et al. The role of hepatitis E virus infection in adult Americans with acute liver failure. Hepatology 2016;64:1870–1880.
doi: 10.1002/hep.28649
pubmed: 27215797
Somasekar S, Lee D, Rule J et al. Viral surveillance in serum samples from patients with acute liver failure by metagenomic next-generation sequencing. Clin Infect Dis 2017;65:1477–1485.
doi: 10.1093/cid/cix596
pubmed: 29020199
pmcid: 5848299
Stravitz RT, Lee WM. Acute liver failure. Lancet 2019;394:869–881.
doi: 10.1016/S0140-6736(19)31894-X
pubmed: 31498101
pmcid: 10836844
Yang E, Peng L, Lee WM. Multiple admissions for acetaminophen over-dose; Acetaminophen frequent fliers, a new entity? Hepatology 2018;68:1197–1199.
doi: 10.1002/hep.29917
pubmed: 29631324
Aboelsoud MM, Javaid AI, Al-Qadi MO, Lewis JH. Hypoxic hepatitis—its biochemical profile, causes and risk factors of mortality in critically ill patients: A cohort study of 565 patients. J Crit Care 2017;41:9–15.
doi: 10.1016/j.jcrc.2017.04.040
pubmed: 28460210
Roberts DW, Lee WM, Hinson J et al. An immunoassay to rapidly measure acetaminophen protein adducts accurately. Clin Gastroenterol Hepatol 2017;15:555–562.
doi: 10.1016/j.cgh.2016.09.007
pubmed: 27641661